arrow
M

Maja Čemažar

institute of oncology ljubljana
H指数:62
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mitochondria‐Targeting Moieties Based on N‐Tethered Pyridinium Cations

基于N-连接吡啶鎓阳离子的线粒体靶向基团

2026-05-200
OA
Correction: Tonon et al. 5-Azacytidine Downregulates the Proliferation and Migration of Hepatocellular Carcinoma Cells In Vitro and In Vivo by Targeting miR-139-5p/ROCK2 Pathway. Cancers 2022, 14, 1630

更正:Tonon et al. 5-Azacytidine通过靶向miR-139-5p/ROCK2通路,在体外和体内下调肝细胞癌细胞的增殖和迁移。Cancers 2022, 14, 1630

Cancers
IF4.4
2026-03-120
OAAI
New mitochondrial KV1.3 conjugates are potent and specific inducers of apoptosis in cancer models

新型线粒体KV1.3共轭物是癌症模型中诱导凋亡的强效且特异性诱导剂

2026-01-150
OAAI
Human papillomavirus-related oropharyngeal squamous cell carcinoma exhibits enhanced radiosensitivity despite limited activation of cytosolic DNA sensing pathways and innate immune responses

人乳头瘤病毒相关的口咽鳞状细胞癌表现出增强的放射敏感性,尽管细胞质DNA传感通路和先天免疫反应的激活有限。

2025-12-010
OAAI
Nanoformulation of a Pin1 inhibitor potentiates the efficacy of liposomal doxorubicin in second-line therapy for ovarian cancer

一种Pin1抑制剂的纳米制剂能够增强脂质体多柔比星在卵巢癌二线治疗中的疗效

2025-11-130
PRE
Synthesis and structure-activity relationship study of novel quinazolin-4(3H)-one derivatives as Toll-like receptor 7 and 8 agonists with immunomodulatory activity

新型喹唑啉-4(3H)-酮衍生物的合成及构效关系研究:作为具有免疫调节活性的Toll样受体7和8激动剂

2025-11-100
OAAI
Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical study
2024-09-272
OAAI
In Vitro and In Vivo Evaluation of the Effects of Drug 2c and Derivatives on Ovarian Cancer Cells

药物2c及其衍生物对卵巢癌细胞作用的体内外评价

2024-05-150
OAAI